Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

February 2023

AGC Biologics and Genenta Expand Development & Manufacturing Agreement

Great news from our zoner AGC Biologics!

Genenta, a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs.


 

Genenta had an existing manufacturing services agreement with Molecular Medicine S.p.A.'s facility in Milan, which was subsequently acquired by AGC Biologics in 2020. The Milan site has been manufacturing LVV (Lenti Viral Vectors) and drug product for Genenta's ongoing programs since 2016, starting with the initial process development steps. The services provided under this existing agreement are in addition to the services that will be provided under the AGC Biologics MSA.

Luca Alberici
General Manager, AGC Biologics Milan

This is the next step in our partnership with Genenta and we are proud to be supporting this innovative product and technology, and helping It reach the next phase of trials. It has been inspiring to watch this once small Italian biotech company reach new heights as they work to bring important treatments to patients around the world. This collaboration highlights the strength of AGC Biologics' viral vector services, our scientific expertise and the decades of scientific GMP manufacturing knowledge we have here in Milan.

READ THE PRESS RELEASE
act

News

There is a lot of news to share about OpenZone. Make sure you're always up-to-date.
all the news